FDA OK for ‘Phantom Recall’ Would Not Excuse J&J, House Says

Johnson & Johnson (J&J) will not be excused for “trying to pull a fast one” with its so-called phantom recall of Motrin, even if the FDA had given it permission for a product removal instead of an official recall, a House committee says. The Committee on Oversight and Government Reform is investigating J&J subsidiary McNeil Consumer Healthcare’s use of contractors to visit gas stations in 2008 to purchase Motrin products that were potentially subpotent, allegedly to avoid conducting a formal recall.
Drug Industry Daily